] i by activating sst 2 receptors. Inhibition of AC activity is only partly responsible for this eect, and other transduction pathways may be involved.
. SRIF ability to lower [Ca 2+ ] i is responsible for its inhibitory action on GH release (Lussier et al., 1991c) .
The GC cell line is derived from a rat pituitary tumour (subclone of the GH 3 mammosomatotroph strain) and represents a homogeneous in vitro model of tumour somatotrophs (Mounier et al., 1995; Kwiecien et al., 1998) . In contrast to GH 3 cells, GC cells release GH but not prolactin. As normal somatotrophs, GC cells exibit rhythmic [Ca 2+ ] i oscillations resulting mainly from Ca 2+ entry through L-type Ca 2+ channels (Kwiecien et al., 1998) . In contrast to normal somatotrophs, however, [Ca 2+ ] i transients do not depend on GHRH, but they occur spontaneously. The function of pacemaker activity in GC cells allows GH secretion that is inhibited by the application of octreotide, a long-lasting SRIF agonist (Mounier et al., 1995) .
SRIF has been shown to play its multiple roles by interacting with speci®c SRIF subtype (sst) receptors (see for review Meyerhof, 1998) . Five receptors have been identi®ed to date and designated sst 1 through sst 5 receptors, each originating from a distinct gene (see for reference Hoyer et al., 1995) . Splice variants of the mouse sst 2 receptor, sst 2(a) and sst 2(b) , have been cloned (Vanetti et al., 1992) . These two isoforms that originate from alternative splicing of the sst 2 receptor mRNA dier in their coupling eciency to adenylyl cyclase (AC) and in agonist-induced receptor desensitization (Vanetti et al., 1993) . In contrast, equivalent rat splice variants display broadly similar pharmacological properties (Schindler et al., 1998) .
